U.S. Pharma Stock News

The New York Stock Exchange, part of Intercontinental Exchange, announced in early 2026 that it will become the U.S. options listings venue for benchmark MSCI indexes, while MSCI separately confirmed it will keep digital asset treasury companies in its Global Investable Market Indexes for the February 2026 review. Together, these moves reinforce the central role of MSCI benchmarks in global risk management, spanning both traditional equity exposures and companies tied to digital...

In recent months, Mercury General highlighted practical, low-cost home security habits for policyholders, while analysts reviewed the insurer’s solid quarterly results and underlying business trends. Despite recent operational strength, analysts now flag Mercury General’s modest 2.4% revenue-growth forecast and below-industry 8.4% return on equity as key concerns. With analysts emphasizing slowing revenue expectations and below-industry return on equity, we’ll now examine how this shifts...

Why Kyndryl Holdings is back on investors’ radar Kyndryl Holdings (KD) has caught investors’ attention after recent share price moves, with the stock showing mixed performance across different timeframes. This is prompting a closer look at how its current fundamentals line up with expectations. See our latest analysis for Kyndryl Holdings. At a share price of $27.09, Kyndryl’s recent 1 day share price return of 1.31% and 7 day share price return of 2.00% sit against a 1 year total shareholder...

If you are wondering whether Celldex Therapeutics at around US$27.76 is priced attractively or not, you are in the right place to size up what the current market tag might be telling you. The stock has had mixed returns, with a 2.2% gain over the last 7 days, a 6.8% decline over 30 days, a 2.8% gain year to date, a 4.6% gain over 1 year, a 40.2% decline over 3 years and a 58.1% gain over 5 years, which can influence how investors think about both potential and risk. Recent attention around...

If you are wondering whether Autoliv's current share price offers good value or is starting to look stretched, the recent numbers give you a clear starting point for that question. Autoliv's stock closed at US$123.25, with returns of 3.8% over 7 days, 4.9% over 30 days, 1.0% year to date, 35.7% over 1 year, 66.6% over 3 years, and 53.1% over 5 years. This provides plenty of history to weigh against the present price. Recent company updates and industry headlines around auto safety suppliers...

Q2 2026 earnings snapshot Cal-Maine Foods (CALM) has just posted another profitable quarter, with Q1 2026 revenue at US$922.6 million and basic EPS of US$4.13 setting the tone for its latest Q2 2026 update. The company has seen revenue move from US$640.8 million in Q4 2024 to US$954.7 million in Q2 2025 and US$1.42 billion in Q3 2025, while quarterly EPS over that stretch ranged from US$2.32 to US$10.42, feeding into trailing twelve month EPS of US$26.12 on revenue of about US$4.4 billion...

Cisco Systems has recently been reported to be in advanced talks to acquire Israeli cybersecurity firm Axonius for about US$2.00 billion, while also emerging as a strategic investor in Elon Musk’s xAI, which closed a very large US$20.00 billion Series E round to expand AI infrastructure and products. Together, these developments highlight how Cisco is coupling potential cybersecurity expansion with direct exposure to large-scale AI buildouts, reinforcing its role at the center of networking,...

In early January 2026, Workiva highlighted softer U.S. labor data and confirmed that Barbara Larson will assume the CFO role on January 20, with leadership emphasizing her experience in supporting a focus on profitable growth ahead of the February 24 earnings release. This combination of macroeconomic developments and a finance leadership transition has sharpened investor attention on how Workiva balances growth ambitions with improving profitability and operating discipline. With Barbara...

Norwegian Cruise Line Holdings (NCLH) has recently shown mixed share performance, with a gain of 27.8% over the past month contrasted by a negative 1 year total return. This has prompted fresh interest in how its fundamentals stack up. See our latest analysis for Norwegian Cruise Line Holdings. The recent 27.8% 1 month share price return and 9.4% 7 day share price return suggest momentum has picked up, even though the 1 year total shareholder return remains a 5.8% decline and the 5 year...

Context for Turning Point Brands stock Turning Point Brands (TPB) has not been in the headlines for a specific news event, so the current focus for investors is how its business profile and recent returns line up with the latest share price. See our latest analysis for Turning Point Brands. Turning Point Brands' share price at $103.25 reflects a mixed recent pattern, with a 19.31% 90 day share price return alongside a year to date decline, while the 1 year total shareholder return of 83.82%...

If you are wondering whether California Resources at around US$44.78 is a bargain or fully priced, the starting point is to understand how its market price stacks up against its fundamentals. The share price has had mixed returns, with around 0.2% over the last week, a 5.2% decline over the past month, a 3.5% decline year to date, an 11.9% decline over one year and a 12.4% and 97.2% return over three and five years respectively. Recent coverage around California Resources has focused on its...

If you are wondering whether Micron Technology's share price matches its underlying value or if expectations have moved ahead of fundamentals, this article is for you. Micron closed at US$339.55, with returns of 19.0% over 7 days, 34.5% over 30 days, 7.7% year to date, 242.7% over 1 year and a very large 3-year gain. Recent attention on Micron has centered on its role in data center and AI related memory, along with broader interest in semiconductor names tied to high performance computing...

In the past week, Rubrik reported quarterly results showing strong year-over-year revenue growth, raised full-year guidance, and highlighted gross margins in the low 80%s alongside solid net revenue retention above 120%. At the same time, management’s outlook pointed to slower upcoming revenue growth and pressure on profitability, prompting investors to reassess the strength and durability of Rubrik’s expansion story. We’ll now examine how management’s signals of slowing near-term revenue...

Precigen, Inc. ( NASDAQ:PGEN ) is possibly approaching a major achievement in its business, so we would like to shine...

India's B2C e-commerce market continues to evolve, with key developments such as the expansion beyond Tier-1 cities, spurred by digital infrastructure and regulatory changes. The market is undergoing consolidation, with conglomerates and large platforms like Reliance Retail, Tata Digital, and Amazon India driving growth and seller inclusion. The increasing use of digital payments, mobile technology, and logistics advancements are contributing to accelerated growth. Companies like Meesho are...

Innventure, Inc.'s (NASDAQ:INV) value has fallen 14% in the last week, but insiders who sold US$2.3m worth of stock...

Jazz Pharmaceuticals (JAZZ) is back in focus after reporting Phase 3 HERIZON-GEA-01 results for its HER2-targeted drug Ziihera in gastroesophageal cancer, highlighting meaningful gains in progression-free and overall survival versus current treatment. See our latest analysis for Jazz Pharmaceuticals. The Ziihera update lands at a time when Jazz Pharmaceuticals’ share price has been relatively firm, with a 90 day share price return of 22.6% and a 1 year total shareholder return of 40.87%. This...

Wondering if Ducommun at about US$100 a share still offers value, or if most of the easy gains are already on the table? This article is built to help you frame that question clearly. The stock recently closed at US$100.04, with returns of 5.2% over 7 days, 11.1% over 30 days, 3.3% year to date, 54.0% over 1 year, 78.1% over 3 years and 79.1% over 5 years, which indicates that many investors are already paying close attention. Recent coverage around Ducommun has highlighted the company as...

If you are wondering whether Eli Lilly's share price still makes sense at around US$1,108, you are not alone. Many investors are asking what they are really paying for at this level. The stock has recently posted returns of 3.1% over the last 7 days, 11.1% over the last 30 days, 2.6% year to date, 41.8% over the last year and a very large gain over 5 years, which naturally raises questions about growth potential and changes in perceived risk. Recent headlines have focused on Eli Lilly's...

If you are wondering whether American Airlines Group at around US$15.99 is a bargain or a value trap, you are not alone. That is exactly what this article is here to unpack. The stock has returned 4.3% over the last 7 days and 7.6% over the last 30 days, while the 1-year return sits at a 9.1% decline and the 3-year and 5-year returns are 4.2% and 3.0% respectively. Recent headlines have continued to focus on American Airlines Group's debt load, cost pressures and the broader recovery path...

Ripple Effect Asset Management recently disclosed a new position in Antero Midstream (AM), buying 510,000 shares worth about US$9.91 million, after the midstream operator reported stronger third quarter cash generation and lower leverage. See our latest analysis for Antero Midstream. Against this backdrop of stronger cash generation and lower leverage, Antero Midstream’s share price has eased in recent months, with a 30 day share price return showing a 7.98% decline and a 90 day share price...

At CES 2026, LG and Samsung unveiled new audio products aimed squarely at Sonos’s core multi-room and home audio market, intensifying competitive pressure on the company’s ecosystem. This fresh wave of big-brand competition comes just as Sonos is working through missed financial targets and projected near-term revenue softness, sharpening investor focus on its ability to defend share and margins. We’ll now examine how this heightened competition from LG and Samsung could influence Sonos’s...

In recent days, attention on Procter & Gamble has intensified as investors look ahead to its January 22, 2026 earnings webcast under new CEO Shailesh Jejurikar, while analysts reassess the consumer staples sector amid cautious U.S. demand and heightened competitive discounting. At the same time, the company faces a mix of opportunities and challenges, from ongoing product liability litigation and shifting analyst views to its positioning in growing skincare and income-focused ETF markets,...

Key Insights Ispire Technology's significant private companies ownership suggests that the key decisions are influenced...